These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 31511186)

  • 1. As Value Assessment Frameworks Evolve, Are They Finally Ready for Prime Time?
    Dubois RW; Westrich K
    Value Health; 2019 Sep; 22(9):977-980. PubMed ID: 31511186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Health Economics Approach to US Value Assessment Frameworks-Introduction: An ISPOR Special Task Force Report [1].
    Neumann PJ; Willke RJ; Garrison LP
    Value Health; 2018 Feb; 21(2):119-123. PubMed ID: 29477388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Yes, Improve the US Value Frameworks, But Recognize They Are Already in Prime Time.
    Neumann PJ
    Value Health; 2019 Sep; 22(9):975-976. PubMed ID: 31511185
    [No Abstract]   [Full Text] [Related]  

  • 4. Review of Recent US Value Frameworks-A Health Economics Approach: An ISPOR Special Task Force Report [6].
    Willke RJ; Neumann PJ; Garrison LP; Ramsey SD
    Value Health; 2018 Feb; 21(2):155-160. PubMed ID: 29477393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ISPOR's Initiative on US Value Assessment Frameworks: A Missed Opportunity for ISPOR and Patients.
    Perfetto EM
    Value Health; 2018 Feb; 21(2):169-170. PubMed ID: 29477396
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward Relevant and Credible Cost-Effectiveness Analyses for Value Assessment in the Decentralized U.S. Health Care System.
    Jansen JP; Incerti D; Curtis JR
    J Manag Care Spec Pharm; 2019 May; 25(5):518-521. PubMed ID: 31039069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].
    Garrison LP; Neumann PJ; Willke RJ; Basu A; Danzon PM; Doshi JA; Drummond MF; Lakdawalla DN; Pauly MV; Phelps CE; Ramsey SD; Towse A; Weinstein MC
    Value Health; 2018 Feb; 21(2):161-165. PubMed ID: 29477394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States.
    Brogan AP; Hogue SL; Vekaria RM; Reynolds I; Coukell A
    J Manag Care Spec Pharm; 2019 Dec; 25(12):1319-1327. PubMed ID: 31778613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A primer on cost-effectiveness in the allergy clinic.
    Shaker M; Greenhawt M
    Ann Allergy Asthma Immunol; 2019 Aug; 123(2):120-128.e1. PubMed ID: 31128234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Approaches to Aggregation and Decision Making-A Health Economics Approach: An ISPOR Special Task Force Report [5].
    Phelps CE; Lakdawalla DN; Basu A; Drummond MF; Towse A; Danzon PM
    Value Health; 2018 Feb; 21(2):146-154. PubMed ID: 29477392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ISPOR's Initiative on US Value Assessment Frameworks: The Use of Cost-Effectiveness Research in Decision Making among US Insurers.
    Solow B; Pezalla EJ
    Value Health; 2018 Feb; 21(2):166-168. PubMed ID: 29477395
    [No Abstract]   [Full Text] [Related]  

  • 13. The ICER Value Framework: Integrating Cost Effectiveness and Affordability in the Assessment of Health Care Value.
    Pearson SD
    Value Health; 2018 Mar; 21(3):258-265. PubMed ID: 29566831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The patient experience of patient-centered communication with nurses in the hospital setting: a qualitative systematic review protocol.
    Newell S; Jordan Z
    JBI Database System Rev Implement Rep; 2015 Jan; 13(1):76-87. PubMed ID: 26447009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Objectives, Budgets, Thresholds, and Opportunity Costs-A Health Economics Approach: An ISPOR Special Task Force Report [4].
    Danzon PM; Drummond MF; Towse A; Pauly MV
    Value Health; 2018 Feb; 21(2):140-145. PubMed ID: 29477391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining the Value of Health Technologies in Latin America: Developments in Value Frameworks to Inform the Allocation of Healthcare Resources.
    Pichon-Riviere A; Garcia-Marti S; Oortwijn W; Augustovski F; Sampietro-Colom L
    Int J Technol Assess Health Care; 2019 Jan; 35(1):64-68. PubMed ID: 30938278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ISPOR's Initiative on US Value Assessment Frameworks: Seeking a Role for Health Economics.
    Sculpher M
    Value Health; 2018 Feb; 21(2):171-172. PubMed ID: 29477397
    [No Abstract]   [Full Text] [Related]  

  • 18. An Overview of Value, Perspective, and Decision Context-A Health Economics Approach: An ISPOR Special Task Force Report [2].
    Garrison LP; Pauly MV; Willke RJ; Neumann PJ
    Value Health; 2018 Feb; 21(2):124-130. PubMed ID: 29477389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ISPOR's Initiative on US Value Assessment Frameworks: An Industry Perspective.
    Burkholder R; Dougherty JS; Neves LA
    Value Health; 2018 Feb; 21(2):173-175. PubMed ID: 29477398
    [No Abstract]   [Full Text] [Related]  

  • 20. Generalisability in economic evaluation studies in healthcare: a review and case studies.
    Sculpher MJ; Pang FS; Manca A; Drummond MF; Golder S; Urdahl H; Davies LM; Eastwood A
    Health Technol Assess; 2004 Dec; 8(49):iii-iv, 1-192. PubMed ID: 15544708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.